Incruse Ellipta (umeclidinium)
Incruse Ellipta 62.5 MCG/INHAL Dry Powder Inhaler, 30 Blisters
NO BOXED WARNING
Dosage & Administration
Dosage & Administration
drug label
Incruse Ellipta Prescribing Information
financial assistance
Incruse Ellipta Financial Assistance Options
patient education
Incruse Ellipta Patient Education
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
people also ask
Incruse Ellipta FAQs
8.1 Pregnancy Risk SummaryInsufficient data are available on the use of umeclidinium in pregnant women to determine a drug-associated risk. Animal studies with pregnant rats and rabbits, exposed to umeclidinium through inhalation or subcutaneous routes, showed no adverse effects on embryofetal development at exposures approximately 50 and 200 times, respectively, the human exposure at the maximum recommended daily inhaled dose (MRHDID).
8.2 Lactation Risk SummaryThere is no information regarding the presence of umeclidinium in human milk, its effects on breastfed infants, or its impact on milk production. Umeclidinium was detected in the plasma of offspring from lactating rats treated with umeclidinium, suggesting its presence in maternal milk. The decision to breastfeed should consider the benefits of breastfeeding along with the clinical need for INCRUSE ELLIPTA, weighing potential effects on the breastfed child from umeclidinium or the maternal condition.
8.4 Pediatric UseINCRUSE ELLIPTA is not approved for use in children, and its safety and efficacy in pediatric patients have not been established.
8.5 Geriatric UseAvailable data do not suggest the need for dosage adjustment of INCRUSE ELLIPTA in geriatric patients. However, some older individuals may exhibit greater sensitivity, although no overall differences in safety or effectiveness were observed in clinical trials between elderly and younger subjects.
8.6 Hepatic ImpairmentPatients with moderate hepatic impairment (Child-Pugh score of 7-9) did not show relevant increases in Cmax or AUC, and protein binding did not differ from healthy controls. Studies in subjects with severe hepatic impairment have not been conducted.
8.7 Renal ImpairmentPatients with severe renal impairment (CrCl <30 mL/min) did not exhibit relevant increases in Cmax or AUC, and protein binding did not differ from healthy controls. No dosage adjustment is required for patients with renal impairment.
FAQ Data Source